• Halozyme director Bernadette Connaughton sold 1,625 common shares on July 1, 2026 at weighted average prices of $76.4 and $77.21.
• Her direct holdings fell to 42,044 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000094), on July 02, 2026, and is solely responsible for the information contained therein.